Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Change in Cash (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Change in Cash for 11 consecutive years, with $558000.0 as the latest value for Q4 2025.

  • Quarterly Change in Cash fell 41.94% to $558000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Dec 2025, up 257.57% year-over-year, with the annual reading at $12.9 million for FY2025, 257.57% up from the prior year.
  • Change in Cash hit $558000.0 in Q4 2025 for Aptevo Therapeutics, down from $11.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $16.2 million in Q1 2021 to a low of -$10.1 million in Q1 2022.
  • Historically, Change in Cash has averaged -$1.0 million across 5 years, with a median of -$2.0 million in 2023.
  • Biggest five-year swings in Change in Cash: crashed 3840.68% in 2023 and later skyrocketed 3822.36% in 2025.
  • Year by year, Change in Cash stood at -$7.1 million in 2021, then soared by 100.83% to $59000.0 in 2022, then plummeted by 3840.68% to -$2.2 million in 2023, then surged by 143.54% to $961000.0 in 2024, then crashed by 41.94% to $558000.0 in 2025.
  • Business Quant data shows Change in Cash for APVO at $558000.0 in Q4 2025, $11.7 million in Q3 2025, and $7.3 million in Q2 2025.